(The AACR-NCI-EORTC international conference was held Nov. 12-16 in San Francisco.) | ||||
Company (Location) |
Product |
Description |
Indication |
Status (Date)# |
ACT Biotech Inc. (San Francisco) |
Telatinib |
An oral VEGF inhibitor |
Gastric cancer |
Phase II data showed patients treated with telatinib and Xeloda and cisplatin who responded with a large decrease of a specific angiogenesis biomarker were found to have a lower risk of disease progression and death compared with patients that had smaller decreases (11/15) |
Cerulean Pharma Inc. (Cambridge, Mass.) |
CRLX101 |
A camptothecin nanoparticle |
Non-small-cell lung cancer |
Phase I/IIa data showed that median progression-free survival time was 4.4 months for 21 of the 38 patients (11/15) |
Enzon Pharmaceuticals Inc. (Piscataway, N.J.) |
EZN-3042 |
An LNA oligonucloetide targeting survivn mRNA |
Advanced solid malignancies |
Phase I data demonstrated good tolerability and antitumor activity (11/15) |
Exelixis Inc. (South San Francisco) |
Cabozantinib |
An inhibitor of MET, RET and VEGFR2 |
Metastatic castration-resistant prostate cancer |
Phase I data suggested that a daily starting dose of 40 mg resulted in high rates of bone scan response assessed by computer-aided detection in men with CRPC and bone metastases; interim data on pain relief and related reduction in narcotic analgesic use showed 56% of patients decreased their dose by at least 30% (11/15) |
Geron Corp. (Menlo Park, Calif.) |
GRN1005 |
Lead LRP-directed peptide-paclitaxel conjugate |
Brain metastases from solid tumors and malignant glioma |
Phase I data demonstrated single-agent clinical activity in both indications (11/16) |
MethylGene Inc. (Montreal) |
MGCD265 |
Oral Met/VEGF receptor tyrosine kinase inhibitor |
Advanced solid cancers |
Phase I data showed the compound was tolerable, with no treatment-related serious adverse events, and showed early signs of clinical benefit (11/15) |
Myrexis Inc. (Salt Lake City) |
MPC-3100 |
Heat-shock protein inhibitor |
Cancer |
Phase I data showed that it was generally safe and well tolerated (11/15) |
Oncolytics Biotech Inc. (Calgary) |
Reolysin |
Intravenous therapy |
Advanced pancreatic cancer |
Interim Phase II data of Reolysin in combination with gemcitabine showed that all but one of 12 patients reported symptomatic improvement, including seven with stable disease for 12 weeks or longer, for a clinical benefit rate of 58% (11/15) |
Oncothyreon Inc. (Seattle) |
PX-866 |
Irreversible, pan-isoform phosphatidylinositol-3-kinase inhibitor |
Advanced cancer |
Two Phase I/II trials showed no dose-limiting toxicities with the combination of docetaxel and PX-866 generally well tolerated; best response was stable disease in 21 of 28 patients and progressive disease in seven patients, for a disease control rate of 75% (11/15) |
Pieris AG (Freising-Weihenstephan, Germany) |
PRS-050 |
Anticalin; an anti-VEGF targeted protein therapeutic |
Advanced solid tumors |
Phase I data showed it was well tolerated, with no maximum-tolerated dose reached, and it demonstrated biological activity, with no immunogenicity (11/16) |
Syndax Pharmaceuticals Inc. (San Francisco and Waltham, Mass.) |
Exemestane |
Hormone therapy |
Postmenopausal estrogen-receptor positive breast cancer |
A pharmacodynamic analysis in a subset of patients demonstrated an association of the pharmacodynamic marker lysine hyperacetylation with clinical outcome (11/15) |
TetraLogic Pharmaceuticals (Malvern, Pa.) |
TL32711 |
Smac mimetic candidate |
Solid tumors and lymphomas |
Phase I data suggested it caused potent and sustained suppression of inhibitor of apoptosis protein in patient peripheral blood mononuclear cells and tumor biopsies over seven days at tolerable dose levels (11/15) |
Ziopharm Oncology Inc. (New York) |
Zymafox |
Palifosfamide |
Non-small-cell lung cancer |
Phase Ib data showed that Zymafos in combination with etoposide and carboplatin can be given at a maximum-tolerated dose of 130 mg/m2, with a dose-limiting toxicity of neutropenic fever (11/15) |
|
Notes: Public biotech company stock symbols can be found in the stock report located on the last two pages of this issue. # The date indicated refers to the BioWorld Today issue in which the news item can be found. | ||||